Table 4 Clinical trials of ICIs, ADCs, and their combined application in TGCT.

From: The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies

Categories

Clinical trials

Phases

Patients

Drugs

Targets

Clinical outcomes

References

ICIs

GU14-206

2

12 TGCT

Pemb

PD-1

mAFP: 615 μg/L; hCG: 4.6 mIU/ml; late relapse (>2 years).

[137]

NCT03403777

2

8 TGCT

Avel

PD-L1

12-week PFS: 0%; mPFS: 0.9 m; mOS: 2.7 m.

[138]

UMIN000028249

2

17 TGCT

Nivo

PD-L1

Nivo was well-tolerated, with only two Grade 3 AV.

[140]

ADCs

NCT01461538

2

40 TGCT

BV

CD30

2/7 patients achieved an OR, including one durable CR and one PR at a single time point.

[143]

NCT02689219

2

18 TGCT

BV

CD30

mAFP: 4.9 μg/L; hCG: 282.5 mIU/ml; late relapse (>2 years).

[145]

Back to article page